Reeling From Ferrlecit Loss, Watson Revamps Branded Sales Strategy
Executive Summary
Watson Pharmaceuticals says the outlook for its most recent launches, Rapaflo and Gelnique, is much improved in 2010, now that it has revamped its branded sales strategy and secured better insurance coverage for these products
You may also be interested in...
Watson Is Bullish On Launching Enhanced Ferrlecit Generic Soon
Watson's own citizen petitions blocking generics won't be an obstacle, company says.
Watson Is Bullish On Launching Enhanced Ferrlecit Generic Soon
Watson's own citizen petitions blocking generics won't be an obstacle, company says.
Watson Acquires Arrow Group And Expands Its Global Footprint
Watson is eying partnerships to further expand branded and generics, but no major deals expected in near term, execs say.